Clinical trials: Sirolimus, completed
Graft Rejection, Kidney Failure
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal…
- Trial name
- NCT00369382
- Testing
- cyclosporine or tacrolimus, sirolimus
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Liver Transplant Recipients
Conversion From Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients
This study aims to determine the safety and efficacy of conversion of sirolimus to everolimus in the maintenance treatment of LT recipients. Patients will be monitored every 12 weeks after the switch of treatment for 48 weeks.
- Trial name
- NCT02482974
- Where
- Turkey (Türkiye)
- Volunteers
- 66 people
- Sponsor
- Ege University
Carcinoma, Renal Cell
Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers
This study will gather data on potential biomarkers in the treatment of advanced renal cell carcinoma (kidney cancer) and investigate their use as indicators of disease response.
- Trial name
- NCT01107509
- Testing
- everolimus
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Birt-Hogg-Dubé Syndrome
Topical Rapamycin for Fibrofolliculomas
The purpose of the study is to determine whether topical application of rapamycin can lead to reduction in size and/or number of fibrofolliculomas in BHD patients and may prevent the growth of new ones.
- Trial name
- NCT00928798
- Testing
- Rapamycin
- Where
- 2 sites in Netherlands
- Volunteers
- 19 people
- Sponsor
- Maastricht University Medical Center
Kidney Transplant Patients
Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients
This study will compare the efficacy and safety of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate mofetil in Kidney Transplant Patients.
- Trial name
- NCT01680952
- Testing
- A) TEST, B) CONTROL
- Where
- 7 sites in South Korea
- Volunteers
- 158 people
- Sponsor
- Yonsei University
HIV-1 Infection
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
The purpose of this study was to find out about the safety of sirolimus in individuals with HIV infection who were also being treated with ART.
- Trial name
- NCT02440789
- Testing
- Sirolimus
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Graft vs Host Disease, Blood and Marrow Transplant (BMT)
Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
- Trial name
- NCT00186667
- Testing
- high dose chemotherapy and autologous hematopoietic cell transplant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Idiopathic Subglottic Tracheal Stenosis
Everolimus Trial in Laryngotracheal Stenosis
Subglottic stenosis (obstructing scar in the larynx and trachea) occurs in patients spontaneously (idiopathic), with autoimmune disease, and after long-term breathing tube placement and can result in communication disability and…
- Trial name
- NCT05153668
- Testing
- Everolimus Oral Tablet
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins University
Systemic Mastocytosis
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
The goal of this clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied.
- Trial name
- NCT00449748
- Testing
- RAD001 (Everolimus)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Renal Allograft
Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts
Evaluate the safety and efficacy of early corticosteroid withdrawal and simultaneous calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained long-term on MMF and sirolimus.
- Trial name
- NCT00374647
- Testing
- mycophenolate mofetil, sirolimus
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Cincinnati
Adult Giant Cell Glioblastoma, Adult Glioblastoma
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II trial to study the effectiveness of CCI-779 in treating patients who have recurrent glioblastoma multiforme. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00016328
- Testing
- temsirolimus, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Liver Transplantation
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
The purpose of this trial was to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients.
- Trial name
- NCT01888432
- Testing
- Everolimus + reduced tacrolimus, Standard tacrolimus
- Where
- 42 sites in United States, Canada and 11 more
- Volunteers
- 285 people
- Sponsor
- Novartis Pharmaceuticals
Renal Transplantation
Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients
This study will assess the safety and efficacy of everolimus with basiliximab, corticosteroids and lower levels versus higher levels of tacrolimus in de novo renal transplant recipients.
- Trial name
- NCT00170833
- Testing
- Everolimus
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
A Study of Diabetic Patients With De Novo Native Coronary Artery Lesions
The main objective of this study is to assess the safety and effectiveness of the CYPHER sirolimus-eluting stent in maintaining minimum lumen diameter in de novo native coronary artery lesions as compared to the uncoated Bx…
- Trial name
- SCORPIUS (NCT00495898)
- Testing
- CYPHER sirolimus-eluting stent, uncoated Bx VELOCITY balloon-expandable stent
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion
The optimal treatment of calcified coronary lesion remained to be elucidated. A Prospective, randomized controlled trial was perform to explore the immediate effect and long-term outcome of rotational atherectomy in patients with…
- Trial name
- NCT01887704
- Testing
- Rotablator, conventional angioplasty, stenting
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Capital Medical University
Hematologic Neoplasms
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
This trial will evaluate the safety and efficacy of post-transplant Cy and sirolimus following reduced intensity allogeneic SCT.
- Trial name
- NCT01244906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northside Hospital, Inc.
Neoplasms
Malignancies in Transplanted Patients
The aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the…
- Trial name
- MALTX (NCT02241564)
- Testing
- Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection, Switch from calcineurin inhibitor to an mTOR inhibitor
- Where
- Sweden
- Volunteers
- 95 people
- Sponsor
- Uppsala University
Highly-sensitized Kidney Transplant Recipients
Role of Everolimus in Highly Sensitized Patients
A growing number of patients on the kidney transplant waiting list are broadly human leukocyte antigen (HLA) sensitized (HS). These patients are unlikely to have a compatible donor.
- Trial name
- NCT01911546
- Testing
- everolimus + low-dose tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Joseph Kahwaji, MD, MPH
Merkel Cell Carcinoma
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
This research study is studying a targeted therapy as a possible treatment for merkel cell carcinoma. The name of the study intervention involved in this study is: MLN0128.
- Trial name
- NCT02514824
- Testing
- MLN0128
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Coronary Artery Disease
Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial
The purpose of this study is to evaluate whether the newly-approved everolimus-eluting stent is not inferior to the sirolimus-eluting stent in terms of the rate of target-lesion revascularization at 1-year and death or myocardial…
- Trial name
- RESET (NCT01035450)
- Testing
- Everolimus-eluting stent, Sirolimus-eluting stent
- Where
- Japan
- Volunteers
- 3,206 people
- Sponsor
- Takeshi Morimoto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.